健帆生物(300529.SZ):預計上半年淨利潤同比增長90%~110%
格隆匯7月8日丨健帆生物(300529.SZ)公佈,預計上半年淨利潤52,700萬元~58,300萬元,比上年同期增長90%~110%,扣非淨利潤50,120萬元~55,720萬元,比上年同期增長91%~112%。
報吿期內,公司外部政策環境得到一定改善。公司持續發揮在血液灌流領域的科技及市場領先優勢,在腎病、肝病、危急重症等領域業務發展態勢良好,實現公司營業收入同比增長。公司以增效降本原則開展各類經營活動,產量規模增加有效降低了單位生產成本,同時期間費用率同比下降,因此歸屬於上市公司股東的淨利潤同比實現大幅增長。2024年上半年非經常性損益對淨利潤的影響金額約為2580萬元,主要系政府補助和購買理財產品的收益。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.